Respiratory

La E, Singer D, Dubois de Gennes C, Graham J, Grace M, Poston S, Verelst F. Public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination in US adults aged 60 years with cardiopulmonary disease. Poster presented at the ISPOR 2025; May 15, 2025. Montreal, Canada.


OBJECTIVES: Risk of severe respiratory syncytialvirus (RSV) disease is increased among adults with cardiopulmonary disease. This study modeled the public health impact and cost-effectiveness of adjuvanted RSVPreF3 vaccination in US adults ≥60 years of age (YOA) with specific prevalent cardiopulmonary diseases.

Singer D, La E, Dubois de Gennes C, Graham J, Grace M, Biundo E, Poston S, Verelst F. Modeled public health impact of adjuvanted RSVPreF3 vaccination in adults aged 50-59 years at increased risk for severe RSV disease in the United States over 5 years. Poster presented at the 13th International Respiratory Syncytial Virus (RSV) Symposium; March 12, 2025. Iguazu Falls, Brazil.


Abstract not available at this time.

Verelst F, La E, Singer D, Graham J, Grace M, Biundo E, Poston S. Modelled public health impact of adjuvanted RSVPreF3 vaccination in adults aged 60 years and older in the United States over 5 years. Poster presented at the 13th International Respiratory Syncytial Virus (RSV) Symposium; March 12, 2025. Iguazu Falls, Brazil.


Abstract not available at this time.

La EM, Sweeney C, Davenport E, Bunniran S. Pharmacy and healthcare provider offices as convenient adult vaccination settings in the US: Patient experiences from a survey of recently-vaccinated adults. Vaccine. 2025 Apr 8;54:127057. doi: 10.1016/j.vaccine.2025.127057


Martin Nguyen A, La Rosa C, Cornell AG, Sher MR, Bernstein JA, Birring SS, DeMuro Romano C, Mayorga M, Milien M, Ervin C. Content validity of the Leicester Cough Questionnaire in adults with refractory or unexplained chronic cough: a qualitative interview study. Ther Adv Respir Dis. 2024 Jan;18:175346662. doi: 10.1177/17534666241274261


Chapman KR, Guyot P, Ledanois O, Soliman M, Wang Z, Xu Y, Nangia A, Cheng W-H. Efficacy of dupilumab versus tezepelumab in asthma patients: matching-adjusted indirect comparison of long-term extension trials. Poster presented at the American College of Allergy, Asthma & Immunology (ACAAI) 2024 Annual Scientific Meeting; October 25, 2024. Boston, MA.


INTRODUCTION: In the absence of head-to-head trials, the long-term relative effi cacy of asthmabiologics can be estimated through indirect treatment comparison after matching baselinepatient characteristics from available single-arm long-term extension trials.

Keogh KA, Dolin P, Kielar D, Shavit A, Rowell J, Edmonds C, Meyers J, Esterberg E, Nham T, Chen SY. Pulmonary and cardiovascular involvement and persistent damage in eosinophilic granulomatosis with polyangiitis: a retrospective analysis of US health insurance claims data. Poster presented at the CHEST 2024; October 9, 2024. Boston, MA. [abstract] Chest. 2024 Oct; 166(4, Suppl):A5373-A57.


PURPOSE: To investigate the degree of pulmonary and cardiovascular involvement and damage in patients with newly diagnosed eosinophilic granulomatosis with polyangiitis (EGPA), using a retrospective analysis of US administrative health insurance claims data (Merative™ MarketScan® databases).

Ghaswalla P, Carrico J, Hicks KA. The annual economic burden of respiratory syncytial virus in adults in the United States. Presented at the 2024 Biomedical Advanced Research and Development Authority George Risi Memorial Journal Club; January 22, 2024.


Abstract not available at this time.

La E, Sweeney C, Davenport E, Bunniran S. Patient experiences with respiratory syncytial virus vaccination during the first season of vaccine availability: results from a survey of recently vaccinated older adults in the United States. Poster presented at the 2024 Virtual Annual Conference on Vaccinology Research; May 8, 2024. Virtual.


La E, Sweeney C, Davenport E, Bunniran S. Pharmacies as convenient adult vaccination settings in the United States: patient experiences from a survey of recently vaccinated adults. Poster presented at the 2024 Virtual Annual Conference on Vaccinology Research; May 8, 2024. Virtual.